Matthias D’Huyvetter (1986) is an assistant professor (0.1ZAP) at the Vrije Universiteit Brussel (VUB) and a postdoctoral fellow of the Research Foundation Flanders-FWO. He graduated in 2009 as Master in Biomedical Sciences at the University of Antwerp. In 2014, he received his PhD in Medical Sciences at the VUB for his work on radiolabelled single-domain antibody fragments as theranostic drugs for cancer treatment. During his PhD, he spent one year at Duke University, North-Carolina USA, under the guidance of Michael Zalutsky. Also in 2014, he co-founded the VUB spin-off company Camel-IDS. In 2019, he obtained the degree of executive Master in Business Administration at Antwerp Management School.
His academic research involves the design and characterization of novel theranostic agents in the field of targeted radionuclide therapy, with a dominant focus single-domain antibody fragments as targeting vehicles and alpha- and beta-particle emitters as toxic payload.